There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cerus (CERS – Research Report), MiMedx Group (MDXG – Research Report) and LENSAR (LNSR – Research Report) with bullish sentiments.
Cerus (CERS)
Craig-Hallum analyst William Bonello maintained a Buy rating on Cerus today. The company’s shares closed last Thursday at $1.70.
According to TipRanks.com, Bonello is ranked #692 out of 8795 analysts.
Cerus has an analyst consensus of Strong Buy, with a price target consensus of $5.50.
See today’s best-performing stocks on TipRanks >>
MiMedx Group (MDXG)
In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on MiMedx Group. The company’s shares closed last Thursday at $6.25.
According to TipRanks.com, Knickerbocker is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MiMedx Group with a $12.25 average price target.
LENSAR (LNSR)
Lake Street analyst Frank Takkinen reiterated a Buy rating on LENSAR today and set a price target of $8.00. The company’s shares closed last Thursday at $3.43.
According to TipRanks.com, Takkinen is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for LENSAR with a $8.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CERS:
- Craig-Hallum starts Cerus at Buy, sees shares more than doubling
- Cerus initiated with a Buy at Craig-Hallum
- FDA approves Cerus’ 12-month shelf life for INTERCEPT platelet processing sets
- Biotech Alert: Searches spiking for these stocks today
- Cathie Wood’s ARK Investment bought 193K shares of Cerus today
